

29th August 2022

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 543308
ISIN: INE967H01017

The Secretary,
National Stock Exchange, Exchange Plaza, 5th
Floor Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Mumbai - 400 051.
Symbol - KIMS
ISIN: INE967H01017

Sub: Execution of Definitive Agreements for acquisition of 51% stake in Spanv Medisearch Lifesciences Private Limited

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") it is hereby informed that M/s. Krishna Institute of Medical Sciences Limited ("Company"), has entered into a Share Subscription Agreement ("SSA") and Shareholders Agreement ("SHA") each dated 29.08.2022 with the existing promoter and certain other shareholders of M/s. Spanv Medisearch Lifesciences Private Limited (Kingsway Hospitals, Nagpur) ("**Target Company**") to acquire 51% of the equity share capital of the Target Company

The Target Company is engaged in the healthcare industry. The said acquisition is subject to the fulfillment of various terms and conditions as specified in the SSA and SPA. The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI circular no. CIPJCFD/CMDI4I2015 dated September 9, 2015, is enclosed as **Annexure I**.

The same is also uploaded on the Company's website at: www.kimshospitals.com > **Stakeholder Relations > Disclosures under Regulation 62 of the SEBI (LODR) Regulations, 2015 > Intimation under Regulation 30.**

We request you to kindly take the same on record.

Thanking You,
Yours truly

For Krishna Institute of Medical Sciences Limited



Umashankar Mantha
Company Secretary and Compliance Officer



Krishna Institute of Medical Sciences Limited

Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: U55101TG1973PLC040558

ANNEXURE -1

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. IR/CFD/CMD/4/2015 dated September 9, 2015.

a)	Name of the target entity, details in brief such as size, turnover etc.,	<p>Name of the target entity: M/s. Spanv Medisearch Lifesciences Private Limited</p> <p>Brief details on the size of the Target Company:</p> <p>M/s. Spanv Medisearch Lifesciences Private Limited is operating a Multi-Specialty Hospital (Kingsway Hospitals), having 300+ beds, at Nagpur.</p> <p>Turnover as on 31.03.2022 is Rs. 173.26 Cr on Standalone basis.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at "arms length":	This deal doesn't fall within related party transaction(s) and the promoter/promoter group/group companies do not have any interest in the said transaction.
c	Industry to which the entity being acquired belongs:	Healthcare Industry
d	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	The acquisition will help the company expand its footprint in the identified cluster to grow i.e. Maharashtra.
e	Brief details of any governmental or regulatory approvals required for the acquisition:	Not applicable
f	Indicative time period for completion of the acquisition	The acquisition will be completed on or before September 30, 2022.



Krishna Institute of Medical Sciences Limited

Minister Road, Secunderabad - 500 003, Telangana, India

Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com

CIN: U55101TG1973PLC040558

G	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash.
h	Cost of acquisition or the price at which the shares are acquired;	The total cost of acquisition is Rs. 80 Cr.
i	Percentage of shareholding/control acquired and / or number of shares acquired;	51% of the issued share capital (fully diluted) will be acquired on or before 30 th September 2022.
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Brief background about the entity acquired: M/s. Spanv Medisearch Lifesciences Private Limited is operating a Multi-Specialty Hospital (Kingsway Hospitals), having 300+ beds, at Nagpur.</p> <p>Date of Incorporation: 01/01/2018</p> <p>History of last 3 years turnover : (Rs. In Cr.)</p> <p>FY 22: Rs. 173.26 FY 21: Rs. 110.30 FY 20: Rs. 145.46</p> <p>Presence: India</p> <p>Other Significant Information: please refer to the aforementioned.</p>

